Pathogenic autoantibodies and diverse immune components

Pathogenic autoantibodies and diverse immune components represent a broad functional category of biological entities that drive the pathology of various autoimmune and inflammatory diseases. Pathogenic autoantibodies are specialized proteins produced by the immune system that mistakenly identify and attack the body's own healthy tissues, leading to chronic inflammation and organ damage (National Institute of Allergy and Infectious Diseases, 2023). The term 'diverse immune components' encompasses a wide range of additional factors, including proinflammatory cytokines, the complement system, and the specific immune cells like B cells and plasma cells that facilitate these responses (Nature Reviews Immunology, 2020). In clinical practice, these components are addressed through various therapeutic modalities: B-cell depleting agents like Rituximab reduce the source of autoantibodies, while neonatal Fc receptor (FcRn) inhibitors like Efgartigimod accelerate the clearance of existing pathogenic IgG (Argenx, 2021). Additionally, complement inhibitors and cytokine antagonists are used to mitigate the downstream damage caused by these immune effectors (Lancet, 2022). Because this entry describes a complex pathological milieu rather than a single molecular receptor or enzyme, it is considered a therapeutic category rather than a discrete drug target.

Other names

AutoantibodySelf-reactive antibodyImmune system componentHumoral immune factor

Therapeutic intervention involves B-cell depletion to stop antibody production, FcRn blockade to increase IgG clearance, and neutralization of cytokines or complement proteins to prevent tissue damage.